Accueil
Envoyer à un ami
Imprimer
Grand
Petit
Partager
ACTUALITES

Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADIANCE Trial of Patients ...


- 16 Septembre 2016 modifié le 1 Janvier 1970


No new safety or tolerability issues were identified during the ongoing blinded extension

(BUSINESS WIRE)-- Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the 96-week blinded extension period (for a total of up to 120 weeks of exposure on treatment) of the RADIANCE phase 2 trial of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS). The results were presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which is being held in London from September 14-17, 2016. ...

Source : http://me-newswire.net//news/18664/en...



ACTUALITES | INTERNATIONAL | TCHAD | POLITIQUE | CULTURE | EXCLUSIF | Revue de Presse | English News | 中國